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Vaccine hypersensitivity - update and overview
Abstract
Concerns about possible reactions to vaccines or vaccinations are frequently raised. However, the rate of
reported vaccine-induced adverse events is low and ranges between 4.8-83.0 per 100,000 doses of the
most frequently used vaccines. The number of true allergic reactions to routine vaccines is not known;
estimations range from 1 per 500,000 to 1 per 1,000,000 doses for most vaccines. When allergens such
as gelatine or egg proteins are components of the formulation, the rate for serious allergic reactions may
be higher. Nevertheless, anaphylactic, potentially life-threatening reactions to vaccines are still a rare
event (approximately 1 per 1,500,000 doses). The variety of reported vaccine-related adverse events is
broad. Most frequently, reactions to vaccines are limited to the injection site and result from a non
specific activation of the inflammatory system by, for example, aluminium salts or the active microbial
components. If allergy is suspected, an accurate examination followed by algorithms is the key for
correct diagnosis, treatment and the decision regarding revaccination in patients with immediate-type
reactions to vaccines.
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Summary
Concerns about possible reactions to vaccines
or vaccinations are frequently raised.
However, the rate of reported vaccine-indu-
ced adverse events is low and ranges between 4.8–
83.0 per 100000 doses of the most frequently used
vaccines. The number of true allergic reactions to
routine vaccines is not known; estimations range
from 1 per 500000 to 1 per 1000000 doses for
most vaccines.When allergens such as gelatine or
egg proteins are components of the formulation,
the rate for serious allergic reactions may be hig-
her. Nevertheless, anaphylactic, potentially life-
threatening reactions to vaccines are still a rare
event (~1 per 1500000 doses). The variety of re-
ported vaccine-related adverse events is broad.
Most frequently, reactions to vaccines are limited
to the injection site and result from a non specific
activation of the inflammatory system by, for ex-
ample, aluminium salts or the active microbial
components.
If allergy is suspected, an accurate examina-
tion followed by algorithms is the key for correct
diagnosis, treatment and the decision regarding
revaccination in patients with immediate-type
reactions to vaccines.
Key words: vaccine allergy; vaccine-induced ad-
verse events; immediate type vaccine allergy; delayed
type vaccine allergy; egg protein; gelatine; antibiotics;
toxoids; macrophagic myofasciitis; revaccination
Abbreviations
AE adverse events
DT diphtheria-tetanus
DTaP diphtheria-tetanus-acellular pertussis
DTR delayed-type reaction
HBV hepatitis B virus
HPV human papilloma virus
ITR immediate-type reaction
JEV Japanese encephalitis virus
MMF macrophagic myofasciitis
MMR measles-mumps-rubella
SPT skin prick test
TBE tick-borne encephalitis
VAERS Vaccine Adverse Event Reporting System
2-PE 2-phenoxy-ethanol
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Introduction
From the mid of the 20th century and since
the propagation of vaccination schedules in vari-
ous countries, many infectious diseases have been
effectively reduced or eliminated and many seque-
lae of infections could be avoided [1, 2]. Vaccines
represent the most effective measures in public
health by controlling and preventing the spread of
infectious diseases [3, 4]. Vaccines and vaccine
components, however, may cause adverse events
(AE) which provide arguments for opponents of
vaccinations against national vaccination recom-
mendations [5, 6]. Nonetheless, the rate of vac-
cine-induced side effects is low. Post-marketing
surveillance data of the national vaccination pro-
grams in children from the Netherlands, Australia
and the US report 4.8 to 83 AE per 100000 given
doses for the most frequently used vaccines [7–9].
Similarly, the Vaccine Adverse Event Reporting
System (VAERS) of the US collected only few re-
ports of AE after administration of commonly
used vaccines (table 1). From 1991 to 2001, the
number of reported mild and even severe AE re-
mained relatively steady (1991: 7.2/100000 given
doses; 2001: 5.8/100000 given doses) [8].
After routine vaccinations, the most common
adverse side effects are symptoms at the injection
site [8]. Local pain, erythema and swelling are the
most frequently reported local side effects [5–7,
10–12]. With respect to systemic adverse reac-
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Table 1
Reported AE per 100000 doses of vaccine
(VAERS 1991–2001, [108]).
Vaccine Reported AE per 100000 doses
Influenza 3
Hepatitis B 11.8
MMR 16.3
DTaP 12.5
tions, fever and irritability are often registered [10,
11, 13]. These usually mild post-vaccination reac-
tions mainly reflect a non-specific stimulation of
the inflammatory system by harmless inactivated
or altered viral or bacterial particles [14–17]. A
number of diseases like asthma, autism, multiple
sclerosis, Guillain-Barré syndrome, inflammatory
bowel disease or sudden infant death have been as-
sumed to be related somehow to vaccinations.
However, none of these associations are based on
scientific or clinical evidence [18–23, 24–28]. For
atopic patients, there is no current evidence for an
increased risk of allergic reactions after vaccina-
tion [29].
Allergies to vaccines only account for a limited
number of all vaccination associated AE. Table 2
lists potential types of immune-mediated side ef-
fects associated with vaccination.
This review focuses on immediate and delayed
type allergic reactions of commonly used vaccines
in Switzerland.
Table 2
Synopsis of potential
immune-mediated
reactions to vaccines.
Immune mediated reaction Frequent clinical manifestation
IgE mediated Urticaria, angioedema, rhinoconjunctivitis, bronchospasm, anaphylaxis, gastrointestinal disorders
(diarrhea, abdominal cramping, vomiting)
Immune complex (IgG) Vasculitis, myocarditis
T-cell mediated Maculopapular exanthema, eczema, acute generalised exanthematous pustulosis (AGEP), erythema
multiforme [109, 110]
Non-IgE mediated
(pseudoallergic)
Urticaria, angioedema, anaphylactoid reactions, gastrointestinal disorders
Autoimmune/inflammatory Thrombocytopenia, vasculitis, polyradiculoneuritis, macrophagic myofasciitis, rheumatoid arthritis,
Reiter’s syndrome, sarcoidosis (juvenile), bullous pemphigoid, lichen planus, Guillain-Barré syndrome,
polymalgia
Immediate type/IgE mediated vaccine allergy
Signs of immediate allergic reactions after
vaccination are predominantly systemic and com-
prise of cutaneous symptoms such as flushing,
urticaria, angioedema, respiratory signs such as
rhinoconjunctivitis or bronchospasm, and cardio-
vascular complications with severe vertigo, faint-
ness, drop of blood pressure and shock starting
within minutes after vaccination.
Immediate, systemic reactions – allergic or
not – following vaccination with frequently used
vaccines are very rare. The average reporting rate
for immediate type reactions (ITR) in children
and adolescents is 0.22 per 100000 doses of vac-
cines. 31% of these patients reported an ITR after
the first vaccination [29]. This observation sug-
gests either a pre-sensitization to a vaccine com-
ponent or non-immunologically mediated reac-
tion.
According to Bohlke et al., reported cases of
potential anaphylaxis after vaccination amount to
0.065 per 100000 given doses of vaccines.None of
the episodes resulted in death [30]. This under-
lines that life-threatening reactions after routine
vaccination are exceptional events. Table 3 sum-
marises the rate of anaphylactic reactions of com-
monly used vaccines.
Table 3
Estimates for
the incidence
of anaphylaxis:
1994–1996 [111].
Vaccine Anaphylactic reactions per 100000 doses
Measles 0.68
Rubella 0.73
Mumps 0.44
Varicella 1.30
HPV 2.60
Vaccine Attenuated virus
Culture media Protein/peptides Hen’s egg, horse serum, murine and simian cells, kidney cells of dog
Additives Antibiotics Neomycin, chlortetracycline, gentamycin, streptomycin, polymyxin B, amphotericin B
Preservatives Formaldehyde, thiomersal, natriumtimerfonat, aluminum, 2-PE
Stabilizers Gelatine, lactose, polysorbate 80/20, polygelines
Contamination Latex
Active agent Toxoids, attenuated pathogens
Table 4
Components
of vaccines
[112–114].
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Almost all components of a vaccine may be
considered as potential triggers of an allergic reac-
tion (table 4).Of particular importance are culture
derived proteins from egg, yeast and gelatine.
Other sources are antibiotics and vaccination an-
tigens. In terms of severe ITR, egg constituents,
gelatine and latex are the most relevant and aller-
genic proteins [31, 32].
Table 5
Content of ovalbu-
min/dose in
Switzerland
(Arzneimittelkompen-
dium der Schweiz).
Vaccine Content of ovalbu-
min/dose
MMR ≤0.001 µg [119]
Influenza vaccines in Switzerland
Fluarix
®
≤1 µg
Influvac
®
≤1 µg
Influvac plus
®
≤0.5 µg
Fluad
®
≤0.2 µg
Inflexal V
®
≤0.05 µg
Mutagrip
®
≤0.05 µg
H1N1 vaccines in Switzerland
Pandemrix
®
Traces (no quantity
specified)
Focetria
®
Traces (no quantity
specified)
Yellow fever vaccine in Switzerland
Stamaril
®
≤1600 µg (!)
Herpes simplex (1 and 2) vaccine in
Switzerland
Lupidon H/G
®
≤50 µg (!)
Delayed-type vaccine allergy and reactions at the site of vaccine injection
Delayed-type reactions (DTR) following vac-
cinations are generally local and confined to the
site of injection. This form of reaction is usually
not considered as an allergy. Such reactions prob-
ably result from non-specific activation of the in-
flammatory system by, for example, high doses of
aluminium salts or microbial components (active
agent) [33].
Rarely, patients hyperimmunized by previous
injections of the vaccine (e.g., tetanus vaccination)
might develop a local immune complex mediated,
so called, Arthus-type reaction at the site of vac-
cine injection [12, 34].
T-cell mediated reactions usually manifest in
the form of local eczema, starting from 2–8 hours
up to 2 days after vaccination. Sometimes the re-
action may extend beyond the injection area or
may even become generalised [35–37].
Even an extensive swelling is usually self-lim-
iting and disappears without complications within
one to four days. Swellings at the injection-site are
no contraindication for further vaccinations [11].
The following vaccines are commonly quoted as
triggers of strong local reactions: polyvalent pneu-
mococcal, influenza, acellular pertussis particu-
larly combined with diphtheria and tetanus toxoid
as well as hepatitis B [34].
Active immunization with tetanus leads to lo-
cal side effects in approximately 80% of adults
[38]. About 2% of child vaccines have, after the
4th or 5th booster dose or after a short injection
interval (<5 to 10 years) with combined diphthe-
ria-tetanus-acellular pertussis (DTaP), local side
effects [39, 40].
Allergenic components in vaccines and their allergenic relevance
Proteins
Egg protein (ovalbumin)
Hen’s egg allergy is a major issue and the most
frequent discussed constituent, in terms of allergic
reactions to vaccines. Egg allergy affects 1.6 to
2.4% of children [41, 42].
Due to cultivation in avian cell lines, vaccines
like measles, mumps and rubella (MMR), influ-
enza, yellow-fever, tick-borne encephalitis (TBE),
herpes simplex (type 1 and 2) and rabies may con-
tain low amounts of ovalbumin. Ovalbumin has
been thought to be responsible for allergic or even
anaphylactic reactions in egg-allergic individuals
[43–46]. Several publications have demonstrated
that allergy to hen’s egg protein is not a contra-
indication for MMR vaccination, even in case of
a severe egg protein hypersensitivity [43, 46, 47].
Whilst MMR, TBE and rabies vaccines are
developed on fibroblasts of chick embryos, herpes
simplex, influenza and yellow fever viruses need to
be cultured in embryonated hen’s eggs.Therefore,
these vaccines may contain higher amounts of egg
proteins (table 5), and are usually contraindicated
for subjects with severe hen’s egg allergy. How-
ever, several case series have demonstrated safe ad-
ministration of the influenza vaccine (<0.6 μg egg
protein/0.5 ml dose) in patients with anaphylaxis
to egg [48–50].
Gelatine
Gelatine is an animal protein derived from the
connective tissue of swine and cattle. It is used as
a stabilizer in attenuated viral containing vaccines.
Gelatine may be added to many vaccines such
as MMR (single or combined), Japanese encepha-
litis virus (JEV), DTaP and varicella. The amount
of gelatine varies from vaccine to vaccine from
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<30 µg to >15500 µg per dose [51]. Gelatine con-
taining vaccines in Switzerland are listed in
table 6.
Severe IgE mediated reactions after vaccina-
tion with gelatine containing compounds are very
rare but have been described afterMMR, varicella,
and JEV [52]. The first vaccine-associated IgE-
mediated reaction was reported after a MMR vac-
cination [53]. The rate of anaphylactic reactions
after measles vaccination was 0.18 per 100000
given doses [51]. IgE antibodies to gelatine have
been demonstrated in 10/36 (28%) subjects with
ITR after MMR vaccination [54], in 93% of 206
patients with anaphylaxis, and in 56% with urti-
caria [55]. In contrast, none of the patients with lo-
cal reactions and none of the control group with-
out AE showed IgE antibodies to gelatine [55].
These findings were linked to the use of gelatine
containing DTaP vaccines as a primary sensitizer
in these patients [55, 56]. Nowadays, all available
DTaP vaccines in Switzerland are free of gelatine
(table 6).
Yeast proteins
Hepatitis B (HBV) and the human papilloma
virus (HPV) vaccines are prepared by harvesting
the antigens from cell cultures of recombinant
strains of Saccharomyces cerevisiae (common bakers’
yeast). In the HBV vaccine, no detectible yeast
DNA and only traces of yeast proteins may be
found [57, 58]. Evidence from the post-marketing
surveillance for vaccine safety suggests that re-
combinant yeast derived HBV and HPV vaccines
pose minimal risk of allergic reactions to yeast
sensitive individuals [59, 60].
Antibiotics
Many vaccines contain traces of antibiotics
like aminoglycosides, polymyxin, chlortetracy-
cline, and the fungicide amphothericin B, to avoid
bacterial and fungal contamination during the
manufacturing process.
To date, there are only few reports on allergic
reactions induced by antibiotics in vaccines.
Neomycin sulphate is widely used in the pro-
duction process of all kind of vaccines. On the
Swiss market, vaccines contain only traces of less
than 25 µg of neomycin per dose [61] (table 7). To
date, one single case of anaphylaxis has been
linked to a neomycin-containing vaccine [62]. It is
a general agreement that patients with anaphylac-
tic reactions to topical or systemic neomycin
should not be vaccinated with neomycin contain-
ing vaccines [63].
In contrast, topical neomycin is known to
elicit a high rate of contact dermatitis [64]. How-
ever, the amount of neomycin found in vaccines is
not believed to trigger DTR [64]. Thus, all these
vaccines may be given to patients with delayed
type sensitization to neomycin [63, 65].
Other antibiotics like streptomycin, gentamy-
cin, polymyxin B sulphate and chlortetracycline
(table 8) have been reported to trigger mild to life-
threatening allergic reactions caused by topical
and/or systemic clinical use [66–71, 72–73], whilst
in term of vaccination they have not yet been
identified as a causative agent of severe allergic re-
actions [37, 74].
Preservatives and stabilizers
Preservatives in vaccines like thiomersal and
2-phenoxyethanol (2-PE) have been identified in
single case reports to trigger allergic reactions af-
ter vaccination [39, 75].
Table 6
Gelatine containing
vaccines in Switzer-
land 2008.
Brand name Addressed disease(s) Gelatine content/
dose
MMR-II Measles, mumps, rubella
(trivalent)
14.5 mg/0.5 ml
Vivotif Typhus Capsule contains
gelatine
Varivax Varicella 12.5 mg/0.5 ml
Zostavax Herpes zoster 15.58 mg/0.5 ml
Table 7
Neomycin containing
vaccines in
Switzerland.
MMR plus M-M-RVaxPro
®
, Priorix
®
, Priorix-Tetra
®
DTP plus Infanrix DTPa-IPV
®
, Infanrix DTPa-IPV + Hib
®
,
Infanrix hexa
®
, Pentavac
®
, Revaxis
®
, Td-Virelon
®
,
Tetravac
®
TBE Encepur N
®
, Encepur N Kinder
®
, FSME-Immun
0.25ml Junior
®
, FSME-Immun CC
®
Hepatitis Twinrix 720/20
®
, HBVAXPRO (5/10/40)
®
,
Havrix 1440/720
®
Cholera Dukoral
®
Rabies Rabipur
®
, Tollwut Impfstoff Mérieux
®
Varicella Varilrix
®
, Varivax
®
Zoster Zostavax
®
Influenza Mutagrip
®
H1N1 Focetria
®
Polio Poliorix
®
Table 8
Antibiotic containing
vaccines [61].
Streptomycin Pentavac
®
, Tetravac
®
, Revaxis
®
, Td-Virelon
®
Gentamicin Fluarix
®
, Influvac
®
, Influvac plus
®
Polymyxin B sulfate Infanrix DTPa-IPV
®
, Infanrix DTPa-IIPV + Hib
®
, Infanrix hexa
®
, Pentavac
®
, Revaxis
®
, Td-Vrirelon
®
, Tetravac
®
,
Poliorix
®
Chlortetracyclin Ecepur N
®
, Encepur Kinder
®
(TBE) and Rabipur
®
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nia,muscle weakness and fever.TheWorld Health
Organisation (WHO) comments that, to date,
there is no evidence of a health risk from alumin-
ium containing vaccines or any justification for
changing current vaccination practices [90].
Toxoids
Toxoids are bacterial toxins whose toxicity is
suppressed either by chemical or temperature
(heat) conditions, while immunogenicity is main-
tained.
Challenges suggest that most toxoid induced
mild to moderate reactions result from a non-spe-
cific activation of the inflammatory system by high
doses of bacterial components [14–17]. That as-
sumption has been supported by good tolerance of
subsequent booster injections of the suspected
vaccines [15–17, 33].
However, in patients with severe urticaria and
angioedema, positive skin and CAP test results to
toxoids have been identified following booster in-
jections of toxoid containing vaccines [33]. Ana-
phylactic reactions to toxoids, however, are very
rare [91–93]. In patients with generalised skin
reactions, such as immediate and accelerated urti-
caria and angioedema, an allergological examina-
tion using the skin prick test (SPT) and determi-
nation of serum specific IgE to anti-toxoid anti-
bodies (diphtheria and tetanus) should be
performed, following booster injections of toxoid-
containing vaccines.
Rare allergenic components in vaccines
Vaccine components like polysorbate (Tween)
[94–96], polygelines [52], amphotericin B [97, 98],
protamine sulphate [99–102] and phenol red [103]
are rarely known to elicit hypersensitivity reac-
tions. In the literature, there is no evidence for hy-
persensitivity reactions of these substances linked
to vaccination.
Thiomersal
For all officially recommended vaccinations in
Switzerland, vaccines without thiomersal are avail-
able [76]. In clinical vaccine-studies, it has been
found that thiomersal is safe even in thiomersal
patch-test positive subjects [77–79]. Recently, one
ITR to thiomersal after influenza vaccination has
been reported [75].
Although the anxiety of thiomersal causing
autism could not be substantiated; thiomersal con-
tinuously disappears from many vaccines [80, 81].
Aluminium
In vaccines, aluminium salts are used as adju-
vants to enhance the immune response [82]. The
most frequent clinical manifestation of a reaction
to aluminium in vaccines is the development of
painful and pruritic nodules at the site of injection
[83]. There are only a few case reports about pa-
tients with hypersensitivity reactions to alumin-
ium developing dermatitis, either localised or gen-
eralised [35].
In recent years, several studies have provided
scientific evidence that there is an association
between aluminium exposure and Alzheimer’s dis-
ease [84, 85]. However, the link between Alzhei-
mer’s disease and aluminium exposure from vacci-
nation remains unclear, since aluminium uptake
by food is much higher than by vaccination [61,
86, 87].
Macrophagic myofasciitis (MMF) is an alu-
minium related disease but is not considered to
be an allergy. MMF was first reported in 1998.
In France over 200 cases have been identified,
and isolated cases have been recorded in Germany,
the US, Spain and Australia. By histopathology,
MMF is characterised by infiltration of muscle tis-
sue by PAS-positive macrophages loaded with alu-
minium hydroxide salts [88, 89]. The condition
manifests by diffuse myalgias, arthralgias, asthe-
Diagnostic approach in patients with vaccine allergy
The Hypersensitivity Working Group of the
Clinical Immunization Safety Assessment (CISA)
Network presented, in September 2008, an algo-
rithm for the treatment of patients with hypersen-
sitivity reactions to vaccines [104].
Table 9 summarises important questions that
have to be addressed during the interview with the
patient to facilitate the classification of the vaccine
induced reaction. The differentiation of an ITR
from a DTR is essential since the allergy testing is
different. Whereas in ITRs the SPT or determi-
nation of specific IgE in serum may be helpful to
identify the causative agent, in DTR patch tests
may be performed.
Therefore, particularly in patients with symp-
toms consistent with IgE-mediated reactions,
allergy testing is indicated, if future doses of the
suspect vaccine will be needed. However, it is
important to mention that the testing in vaccine
hypersensitivity is not standardised and not vali-
dated. It is necessary to use the intact vaccine for
skin testing preferably from the same manufac-
turer and in some instances it might be helpful to
test with specific vaccine components when avail-
able. Skin tests are performed according to the
general guidelines as for other allergic diseases
(fig. 1). Due to a high incidence of false positive
reactions due to inherent vaccine irritation, intra-
Table 9
Patient’s history
and clinic.
Timing of the symptoms relative to vaccine administration
(immediate, delayed, not allergic)
Characteristic symptoms (urticaria, angioedema, rhinoconjuncti-
vitis, bronchospasm, eczema, maculopapular rash)
Localisation of the lesion (local at the injection site, generalised)
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dermal skin testing with undiluted compounds
should be omitted. Furthermore, it is important to
recognize that localised DTRs are common after
testing with undiluted and 1:10 concentrations of
many vaccines and are not diagnostic for an al-
lergy.
In case a sensitization to vaccine compounds
could be excluded, patients with ITR can be revac-
cinated, however, under controlled conditions in
an appropriate setting.
Figure 1
Diagnostic course of
SPTing with vaccines.
SPTing with vaccine or vaccine components
(e.g., hen’s egg, gelatine) at a 1:10 dilution
SPT using the undiluted vaccine or compounds
intradermal testing at a 1:100 concentration of the vaccine
intradermal skin testing at a concentration of 1:10
negative
negative
negative
Cave: intradermal skin testing at a 1:10 concentration might
elicit irritative skin reactions (false positive such as for
instance influenza vaccine).
Revaccination of patients with suspected hypersensitivity reactions
Decisions about revaccination should be made
on the basis of a case-by-case risk/benefit analysis.
For patients with an ITR and in need of revacci-
nation, the following procedure may be consid-
ered [104]:
1. Alternative preparations without suspected al-
lergens should always be used when available.
2. If testing has been inconclusive and multiple
vaccines are potentially implicated, the vac-
cines should be given individually, on separate
days.
3. If SPTs are negative, and there is no history
of anaphylaxis, the vaccine can be given in a
single dose followed by observation of the pa-
tient for one hour.
4. If SPTs are negative but the history is sugges-
tive for anaphylaxis or other serious reactions,
10% of the dose of the full-strength of the
vaccine could be administered followed by ob-
servation of the patient for at least 30 minutes.
If there are no signs of any reaction, the re-
maining part of the vaccine can be given and
the patient must be observed for another hour.
5. If SPTs are positive for the vaccine and/or one
of its components and there is absolute need
for vaccination, fractionate vaccination ac-
cording to the recommendation of the Ameri-
can Academy of Pediatrics [105] (table 10)
may be considered. Doses are given at inter-
vals of 15 to 30 minutes until the full dose has
been applied or until the first signs of an AE is
observed. For some cases, and according to
the history, the time interval may be extended.
In case of AE two options may be followed:
a. Withhold additional doses of the vaccine,
b. Pre-medication with antihistamines and
oral corticosteroids before further up-dosing.
For patients with DTRs, the approach to re-
vaccination will be based on the nature of the pre-
vious reaction, because patch testing will not be
helpful in predicting future risk. The decision to
revaccinate should be made on an individual basis,
depending on the importance of revaccination and
the nature of the previous reaction. Patients with
previous DTRs can generally receive the full dose
of the vaccine
Alternative algorithm for revaccination of
patients with suspected hypersensitivity to egg
(ovalbumin)
Lavi et al. showed that egg allergic children
with a negative SPT to the suspected vaccine, tol-
erated a complete dose of ovalbumin-containing
vaccines [106]. If SPTing is positive, a risk-benefit
analysis is indicated or, if necessary, a two-dose
protocol should be administered when the availa-
ble vaccine preparation contains more than
1.2 µg/mL of egg protein (see table 5): Under pre-
medication (antihistamines, steroids) injection of
1/10 of the total load, is followed after 30 minutes
a) 0.05 mL of 1:10 dilution
b) 0.05 mL of full strength
c) 0.10 mL of full strength
d) 0.15 mL of full strength
e) 0.20 mL of full strength
f) for vaccines that require a volume of 1.0 mL, the remaining
0.5 mL dose can be added
Table 10
Proposal of adminis-
tration of vaccines in
patients with positive
SPT for the respec-
tive vaccine and
absolute need for
vaccination [105].
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Figure 2
Algorithm for the immunisation of indviduals allergic to egg with influenza vaccine by
Erlewyn-Lajeunesse et al. [107].
* Able to eat a portion of eggs (not just egg when baked in foods such as in cakes
and biscuit) without immediate allergic reactions
** A positive SPT, specific IgE, food challenge
*** A history of a severe allergic reaction affecting at least one of the following
areas: airway (throat tightness, sensation of closure, stridor, hoarseness),
breathing (tachypnoea, respiratory distress, dyspnoea, wheeze, hypoxia),
circulation collapse, hypotension, shock with or without loss of conciousness,
severe abdominal pain)
**** Uncontrolled asthma or using preventative drugs
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